Skip to main content

Advertisement

SpringerLink
Log in

SARS-CoV-2-Infektion und Autoimmunität

SARS-CoV-2 infection and autoimmunity

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Schon zu Beginn der Corona-Pandemie 2020 wurde SARS-CoV‑2 als „Autoimmunvirus“ bezeichnet. Seither gibt es zahlreiche Berichte über das vermehrte Auftreten von Autoantikörpern und Autoimmunphänomenen nach SARS-CoV-2-Infektionen. Dabei können Autoantikörper einerseits den Krankheitsverlauf beeinflussen, andererseits zur Erstmanifestation von Autoimmunerkrankungen führen. Zudem wird auch für die Pathogenese von Post-COVID eine Rolle von Autoantikörpern diskutiert. Im vorliegenden Beitrag werden dazu wesentliche Aspekte und Studien aufgeführt, und es wird dargestellt, welche möglichen therapeutischen Konsequenzen sich aus den Erkenntnissen ergeben.

Abstract

Even in the early phase of the corona pandemic in 2020, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) was referred to as an “autoimmune virus”. Since then, there have been numerous reports on the increased incidence of autoantibodies and autoimmune phenomena after SARS-CoV‑2 infections. On the one hand, autoantibodies can influence the course of the disease and on the other hand, they can lead to the first manifestation of new autoimmune diseases. In addition, a role of autoantibodies in the pathogenesis of post-coronavirus disease (post-COVID) is discussed. In the present review article, important aspects and studies are listed and the possible therapeutic consequences resulting from the findings are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abdelwahab OA, Diab RA, Elsaeidy KS et al (2023) Efficacy of therapeutic plasma exchange in patients with severe COVID-19: a systematic review and meta-analysis. Rev Med Virol 33(3):e2435

    Article  CAS  PubMed  Google Scholar 

  2. Acosta-Ampudia Y, Monsalve DM, Rojas M et al (2022) Persistent autoimmune activation and proinflammatory state in post-coronavirus disease 2019 syndrome. J Infect Dis 225(12):2155–2162

    Article  CAS  PubMed  Google Scholar 

  3. Baechle C, Eckert A, Kamrath C et al (2023) Incidence and presentation of new-onset type 1 diabetes in children and adolescents from Germany during the COVID-19 pandemic 2020 and 2021: Current data from the DPV Registry. Diabetes Res Clin Pract 197:110559

    Article  CAS  PubMed  Google Scholar 

  4. Bastard P, Rosen LB, Zhang Q et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370(6515)

  5. Bastard P, Orlova E, Sozaeva L et al (2021) Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS‑1. J Exp Med 218(7)

  6. Cabral-Marques O, Moll G, Catar R et al (2023) Autoantibodies targeting G protein-coupled receptors: an evolving history in autoimmunity. Report of the 4th international symposium. Autoimmun Rev 22(5):103310

    Article  CAS  PubMed  Google Scholar 

  7. Chang R, Chen Y‑TT, Wang S‑I et al (2023) Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine 56:101783

    Article  PubMed  PubMed Central  Google Scholar 

  8. Chang SE, Feng A, Meng W et al (2021) New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 12(1):5417

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

  9. Dotan A, David P, Arnheim D et al (2022) The autonomic aspects of the post-COVID 19 syndrome. Autoimmun Rev 21(5):103071

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Feng A, Yang EY, Moore AR et al (2023) Autoantibodies are highly prevalent in non-SARS-CoV‑2 respiratory infections and critical illness. JCI Insight 8(3)

  11. Fonseca-González G, Alamilla-Sánchez M, García-Macas V et al (2023) Impact of plasmapheresis on severe COVID-19. Sci Rep 13(1):163

    Article  PubMed  PubMed Central  ADS  Google Scholar 

  12. Garmendia JV, García AH, de Sanctis CV et al (2022) Autoimmunity and Immunodeficiency in Severe SARS-CoV‑2 Infection and Prolonged COVID-19. Curr Issues Mol Biol 45(1):33–50

    Article  PubMed  PubMed Central  Google Scholar 

  13. Halpert G, Shoenfeld Y (2020) SARS-CoV‑2, the autoimmune virus. Autoimmun Rev 19(12):102695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Høeg TB, Ladhani S, Prasad V (2023) How methodological pitfalls have created widespread misunderstanding about long COVID. BMJ Evidence-Based Medicine

    Book  Google Scholar 

  15. Kamrath C, Mönkemöller K, Biester T et al (2020) Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA 324(8):801–804

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Klein J, Wood J, Jaycox J et al (2023) Distinguishing features of Long COVID identified through immune profiling. Nature

  17. Koczulla AR, Ankermann T, Behrends U et al (2022) S1-Leitlinie Long‑/Post-COVID. Pneumologie 76(12):855–907

    Article  CAS  PubMed  Google Scholar 

  18. Loske J, Röhmel J, Lukassen S et al (2022) Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV‑2 infection in children. Nat Biotechnol 40(3):319–324

    Article  CAS  PubMed  Google Scholar 

  19. Meisel C, Akbil B, Meyer T et al (2021) Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. J Clin Invest 131(14)

  20. Puel A, Bastard P, Bustamante J et al (2022) Human autoantibodies underlying infectious diseases. J Exp Med 219(4)

  21. Salmi H, Heinonen S, Hästbacka J et al (2022) New-onset type 1 diabetes in finnish children during the COVID-19 pandemic. Arch Dis Child 107(2):180–185

    Article  PubMed  Google Scholar 

  22. Scheibenbogen C, Loebel M, Freitag H et al (2018) Immunoadsorption to remove β2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE 13(3):e193672

    Article  PubMed  PubMed Central  Google Scholar 

  23. Shankar P, Singh J, Joshi A et al (2022) Organ involvement in COVID-19: a molecular investigation of autopsied patients. Microorganisms 10(7)

  24. Sher EK, Ćosović A, Džidić-Krivić A et al (2023) Covid-19 a triggering factor of autoimmune and multi-inflammatory diseases. Life Sci 319:121531

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sotzny F, Filgueiras IS, Kedor C et al (2022) Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in post COVID syndrome correlate with symptom severity. Front Immunol 13:981532

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Steels S, van Elslande J, de Munter P et al (2022) Transient increase of pre-existing anti-IFN-α2 antibodies induced by SARS-coV‑2 infection. J Clin Immunol 42(4):742–745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tesch F, Ehm F, Vivirito A et al (2023) Incident autoimmune diseases in association with SARS-CoV‑2 infection: a matched cohort study. Clin Rheumatol

  28. Unsworth R, Wallace S, Oliver NS et al (2020) New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care 43(11):e170–e171

    Article  CAS  PubMed  Google Scholar 

  29. Wang EY, Mao T, Klein J et al (2021) Diverse functional autoantibodies in patients with COVID-19. Nature 595(7866):283–288

    Article  CAS  PubMed  ADS  Google Scholar 

  30. Wang X, Tang Q, Li H et al (2023) Autoantibodies against type I interferons in COVID-19 infection: a systematic review and meta-analysis. Int J Infect Dis 130:147–152

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhang Q, Pizzorno A, Miorin L et al (2022) Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med 219(11)

Download references

Author information

Authors and Affiliations

  1. Pädiatrische Rheumatologie und Immunologie, Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsmedizin Greifswald, KöR, Ferdinand-Sauerbruch-Str., 17475, Greifswald, Deutschland

    Almut Meyer-Bahlburg

Authors
  1. Almut Meyer-Bahlburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Almut Meyer-Bahlburg.

Ethics declarations

Interessenkonflikt

A. Meyer-Bahlburg gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von der Autorin keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

Hans-Iko Huppertz, Bremen

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meyer-Bahlburg, A. SARS-CoV-2-Infektion und Autoimmunität. Z Rheumatol 83, 34–40 (2024). https://doi.org/10.1007/s00393-023-01455-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-023-01455-x

Schlüsselwörter

Keywords

Search

Navigation